Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.
AZD6244 and MK2206 are targeted small-molecule drugs that inhibit MEK and AKT respectively. The efficacy of this combination in lung cancer is unknown. Our previous work showed the importance of activated AKT in mediating resistance of non-small cell lung cancer (NSCLC) to AZD6244. Thus we hypothesi...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-11-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0014124&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133742159396864 |
|---|---|
| author | Jieru Meng Bingbing Dai Bingliang Fang B Nebiyou Bekele William G Bornmann Duoli Sun Zhenghong Peng Roy S Herbst Vassiliki Papadimitrakopoulou John D Minna Michael Peyton Jack A Roth |
| author_facet | Jieru Meng Bingbing Dai Bingliang Fang B Nebiyou Bekele William G Bornmann Duoli Sun Zhenghong Peng Roy S Herbst Vassiliki Papadimitrakopoulou John D Minna Michael Peyton Jack A Roth |
| author_sort | Jieru Meng |
| collection | DOAJ |
| description | AZD6244 and MK2206 are targeted small-molecule drugs that inhibit MEK and AKT respectively. The efficacy of this combination in lung cancer is unknown. Our previous work showed the importance of activated AKT in mediating resistance of non-small cell lung cancer (NSCLC) to AZD6244. Thus we hypothesized that dual inhibition of both downstream MEK and AKT pathways would induce synergistic antitumor activity. In this study, we evaluated the efficacy of AZD6244 and MK2206 individually on a large panel of lung cancer cell lines. Then, we treated 28 human lung cancer cell lines with a combination of AZD6244 and MK2206 at clinically applicable drug molar ratios. The AZD6244-MK2206 combination therapy resulted in a synergistic effect on inhibition of lung cancer cell growth compared to the results of single drug treatment alone. MK2206 enhanced AZD6244-induced Bim overexpression and apoptosis in A549 and H157 cells. When we tested the combination of AZD6244 and MK2206 at ratios of 8∶1, 4∶1, 2∶1, and 1∶8, we found that the synergistic effect of the combination therapy was ratio-dependent. At ratios of 8∶1, 4∶1, and 2∶1, the drug combination consistently demonstrated synergy, whereas decreasing the ratio to 1∶8 resulted in a loss of synergy and produced an additive or antagonistic effect in most cell lines. Furthermore, the AZD6244-MK2206 combination therapy showed synergy in the suppression of A549 and H157 xenograft tumor growth and increased mean animal survival time. The AZD6244-MK2206 combination therapy resulted in effective inhibition of both p-ERK and p-AKT expression in tumor tissue. In addition, a significant increase of apoptosis was detected in tumor tissue from mice treated with AZD6244-MK2206 compared with that from the single agent treated mice. Our study suggests that the combination of AZD6244 and MK2206 has a significant synergistic effect on tumor growth in vitro and in vivo and leads to increased survival rates in mice bearing highly aggressive human lung tumors. |
| format | Article |
| id | doaj-art-5a2c9bf45d224b3b8e13b8bd8bb0bb5d |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2010-11-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-5a2c9bf45d224b3b8e13b8bd8bb0bb5d2025-08-20T02:31:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-11-01511e1412410.1371/journal.pone.0014124Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo.Jieru MengBingbing DaiBingliang FangB Nebiyou BekeleWilliam G BornmannDuoli SunZhenghong PengRoy S HerbstVassiliki PapadimitrakopoulouJohn D MinnaMichael PeytonJack A RothAZD6244 and MK2206 are targeted small-molecule drugs that inhibit MEK and AKT respectively. The efficacy of this combination in lung cancer is unknown. Our previous work showed the importance of activated AKT in mediating resistance of non-small cell lung cancer (NSCLC) to AZD6244. Thus we hypothesized that dual inhibition of both downstream MEK and AKT pathways would induce synergistic antitumor activity. In this study, we evaluated the efficacy of AZD6244 and MK2206 individually on a large panel of lung cancer cell lines. Then, we treated 28 human lung cancer cell lines with a combination of AZD6244 and MK2206 at clinically applicable drug molar ratios. The AZD6244-MK2206 combination therapy resulted in a synergistic effect on inhibition of lung cancer cell growth compared to the results of single drug treatment alone. MK2206 enhanced AZD6244-induced Bim overexpression and apoptosis in A549 and H157 cells. When we tested the combination of AZD6244 and MK2206 at ratios of 8∶1, 4∶1, 2∶1, and 1∶8, we found that the synergistic effect of the combination therapy was ratio-dependent. At ratios of 8∶1, 4∶1, and 2∶1, the drug combination consistently demonstrated synergy, whereas decreasing the ratio to 1∶8 resulted in a loss of synergy and produced an additive or antagonistic effect in most cell lines. Furthermore, the AZD6244-MK2206 combination therapy showed synergy in the suppression of A549 and H157 xenograft tumor growth and increased mean animal survival time. The AZD6244-MK2206 combination therapy resulted in effective inhibition of both p-ERK and p-AKT expression in tumor tissue. In addition, a significant increase of apoptosis was detected in tumor tissue from mice treated with AZD6244-MK2206 compared with that from the single agent treated mice. Our study suggests that the combination of AZD6244 and MK2206 has a significant synergistic effect on tumor growth in vitro and in vivo and leads to increased survival rates in mice bearing highly aggressive human lung tumors.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0014124&type=printable |
| spellingShingle | Jieru Meng Bingbing Dai Bingliang Fang B Nebiyou Bekele William G Bornmann Duoli Sun Zhenghong Peng Roy S Herbst Vassiliki Papadimitrakopoulou John D Minna Michael Peyton Jack A Roth Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS ONE |
| title | Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. |
| title_full | Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. |
| title_fullStr | Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. |
| title_full_unstemmed | Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. |
| title_short | Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. |
| title_sort | combination treatment with mek and akt inhibitors is more effective than each drug alone in human non small cell lung cancer in vitro and in vivo |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0014124&type=printable |
| work_keys_str_mv | AT jierumeng combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT bingbingdai combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT bingliangfang combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT bnebiyoubekele combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT williamgbornmann combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT duolisun combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT zhenghongpeng combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT roysherbst combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT vassilikipapadimitrakopoulou combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT johndminna combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT michaelpeyton combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo AT jackaroth combinationtreatmentwithmekandaktinhibitorsismoreeffectivethaneachdrugaloneinhumannonsmallcelllungcancerinvitroandinvivo |